CoChat

Key considerations in the treatment of complicated staphylococcal infections

Jones, R.N. · 2008 · Clinical Microbiology and Infection
Cited by 22

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1469-0691.2008.01923.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 55

  1. Gonzalez-Romo, 2003, Prevalence and treatment of Gram-positive infections in internal medicine departments of Spanish hospitals: IGP Study, Rev Esp Quimioter, 16, 428
  2. Bouza, 2001, Infections caused by Gram-positive bacteria: situation and challenges of treatment, Clin Microbiol Infect, 7, iii, 10.1046/j.1469-0691.2001.00064.x · doi:10.1046/j.1469-0691.2001.00064.x
  3. Lepape, 2003, Epidemiology of Gram-positive infections in France: changing resistance, Presse Med, 32, S5
  4. Schaberg, 1991, Major trends in the microbial etiology of nosocomial infection, Am J Med, 91, 72S, 10.1016/0002-9343(91)90346-Y · DOI · Paper page
  5. Wisplinghoff, 2004, Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study, Clin Infect Dis, 39, 309, 10.1086/421946 · DOI · Paper page
  6. Moet, 2007, Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004), Diagn Microbiol Infect Dis, 57, 7, 10.1016/j.diagmicrobio.2006.05.009 · DOI · Paper page
  7. Finch, 2006, Gram-positive infections: lessons learnt and novel solutions, Clin Microbiol Infect, 12, 3, 10.1111/j.1469-0691.2006.01624.x · DOI
  8. Jones, 2006, Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains, Clin Infect Dis, 42, S13, 10.1086/491710 · DOI · Paper page
  9. Whitby, 2001, Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis, Med J Aust, 175, 264, 10.5694/j.1326-5377.2001.tb143562.x · DOI · Paper page
  10. Cosgrove, 2003, Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis, Clin Infect Dis, 36, 53, 10.1086/345476 · DOI · Paper page
  11. Boyle-Vavra, 2007, Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton–Valentine leukocidin, Lab Invest, 87, 3, 10.1038/labinvest.3700501 · DOI · Paper page
  12. Vandenesch, 2003, Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton–Valentine leukocidin genes: worldwide emergence, Emerg Infect Dis, 9, 978, 10.3201/eid0908.030089 · DOI · Paper page
  13. Weber, 2005, Community-associated methicillin-resistant Staphylococcus aureus, Clin Infect Dis, 41, S269, 10.1086/430788 · DOI · Paper page
  14. Beam, 2006, Community-acquired methicillin-resistant Staphylococcus aureus: prevalence and risk factors, J Athl Train, 41, 337
  15. Friedman, 2002, Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections, Ann Intern Med, 137, 791, 10.7326/0003-4819-137-10-200211190-00007 · DOI · Paper page
  16. 2001, Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison—Mississippi 2000, MMWR, 50, 919
  17. 2003, Methicillin-resistant Staphylococcus aureus infections in correctional facilities—Georgia, California, and Texas, 2001–2003, MMWR, 52, 992
  18. Begier, 2004, A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns, Clin Infect Dis, 39, 1446, 10.1086/425313 · DOI · Paper page
  19. Nguyen, 2005, Recurring methicillin-resistant Staphylococcus aureus infections in a football team, Emerg Infect Dis, 11, 526, 10.3201/eid1104.041094 · DOI · Paper page
  20. 2003, Methicillin-resistant Staphylococcus aureus infections among competitive sports participants—Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000–2003, MMWR, 52, 793
  21. Zinderman, 2004, Community-acquired methicillin-resistant Staphylococcus aureus among military recruits, Emerg Infect Dis, 10, 941, 10.3201/eid1005.030604 · DOI · Paper page
  22. Ellis, 2004, Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers, Clin Infect Dis, 39, 971, 10.1086/423965 · DOI · Paper page
  23. Elston, 2007, Community-acquired methicillin-resistant Staphylococcus aureus, J Am Acad Dermatol, 56, 1, 10.1016/j.jaad.2006.04.018 · DOI · Paper page
  24. Gemmell, 2006, Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK, J Antimicrob Chemother, 57, 589, 10.1093/jac/dkl017 · DOI · Paper page
  25. Stevens, 2005, Practice guidelines for the diagnosis and management of skin and soft-tissue infections, Clin Infect Dis, 41, 1373, 10.1086/497143 · DOI · Paper page
  26. Chang, 2003, Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study, Medicine (Baltimore), 82, 333, 10.1097/01.md.0000091184.93122.09 · DOI · Paper page
  27. Finch, 2005, Safety and efficacy of glycopeptide antibiotics, J Antimicrob Chemother, 55, ii5, 10.1093/jac/dki004 · DOI
  28. Appelbaum, 2006, The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, Clin Microbiol Infect, 12, 16, 10.1111/j.1469-0691.2006.01344.x · DOI · Paper page
  29. Tenover, 1998, Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides, J Clin Microbiol, 36, 1020, 10.1128/JCM.36.4.1020-1027.1998 · DOI · Paper page
  30. Flannagan, 2003, Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotype, Antimicrob Agents Chemother, 47, 3954, 10.1128/AAC.47.12.3954-3959.2003 · DOI · Paper page
  31. Weigel, 2003, Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus, Science, 302, 1569, 10.1126/science.1090956 · DOI · Paper page
  32. Tenover, 2004, Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania, Antimicrob Agents Chemother, 48, 275, 10.1128/AAC.48.1.275-280.2004 · DOI · Paper page
  33. Arthur, 1993, Genetics and mechanisms of glycopeptide resistance in enterococci, Antimicrob Agents Chemother, 37, 1563, 10.1128/AAC.37.8.1563 · DOI · Paper page
  34. Noble, 1992, Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus, FEMS Microbiol Lett, 72, 195, 10.1111/j.1574-6968.1992.tb05089.x · DOI · Paper page
  35. Bush, 2004, Vancomycin-resistant Staphylococcus aureus in the clinic: not quite armageddon, Clin Infect Dis, 38, 1056, 10.1086/382366 · doi:10.1086/382366
  36. Wang, 2006, Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period, J Clin Microbiol, 44, 3883, 10.1128/JCM.01388-06 · DOI · Paper page
  37. Maor, 2007, Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) bacteremia in a tertiary care center, J Clin Microbiol, 45, 1511, 10.1128/JCM.01262-06 · DOI · Paper page
  38. Walsh, 2002, The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus, Annu Rev Microbiol, 56, 657, 10.1146/annurev.micro.56.012302.160806 · DOI · Paper page
  39. Sancak, 2005, Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital, J Antimicrob Chemother, 56, 519, 10.1093/jac/dki272 · DOI · Paper page
  40. Fridkin, 2001, Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know, Clin Infect Dis, 32, 108, 10.1086/317542 · DOI · Paper page
  41. Tenover, 2007, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus, Clin Infect Dis, 44, 1208, 10.1086/513203 · DOI · Paper page
  42. Sherris, 1986, Problems in in vitro determination of antibiotic tolerance in clinical isolates, Antimicrob Agents Chemother, 30, 633, 10.1128/AAC.30.5.633 · DOI
  43. Tuomanen, 1986, Antibiotic tolerance among clinical isolates of bacteria, Antimicrob Agents Chemother, 30, 521, 10.1128/AAC.30.4.521 · DOI · Paper page
  44. May, 1998, Glycopeptide tolerance in Staphylococcus aureus, J Antimicrob Chemother, 42, 189, 10.1093/jac/42.2.189 · doi:10.1093/jac/42.2.189
  45. Steinkraus, 2007, Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant Saureus (MRSA) blood isolates from 2001–05, J Antimicrob Chemother, 60, 788, 10.1093/jac/dkm258 · DOI · Paper page
  46. Hidayat, 2006, High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity, Arch Intern Med, 166, 2138, 10.1001/archinte.166.19.2138 · DOI · Paper page
  47. Sakoulas, 2004, Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia, J Clin Microbiol, 42, 2398, 10.1128/JCM.42.6.2398-2402.2004 · DOI · Paper page
  48. Small, 1990, Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users, Antimicrob Agents Chemother, 34, 1227, 10.1128/AAC.34.6.1227 · DOI · Paper page
  49. Howden, 2004, Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility, Clin Infect Dis, 38, 521, 10.1086/381202 · DOI · Paper page
  50. Appelbaum, 2006, MRSA—the tip of the iceberg, Clin Microbiol Infect, 12, 3, 10.1111/j.1469-0691.2006.01402.x · DOI · Paper page
  51. Finch, 2006, Antibiotic resistance—action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12–13 December 2005, J Antimicrob Chemother, 58, i3, 10.1093/jac/dkl373 · DOI · Paper page
  52. Alder, 2004, The advantage of bactericidal drugs in the treatment of infection, Curr Infect Dis Rep, 6, 251, 10.1007/s11908-004-0042-1 · DOI
  53. Pankey, 2004, Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections, Clin Infect Dis, 38, 864, 10.1086/381972 · DOI · Paper page
  54. Shah, 2005, The need for new therapeutic agents: what is the pipeline, Clin Microbiol Infect, 11, 36, 10.1111/j.1469-0691.2005.01141.x · DOI
  55. Finberg, 2004, The importance of bactericidal drugs: future directions in infectious disease, Clin Infect Dis, 39, 1314, 10.1086/425009 · DOI · Paper page

Cited by

See all 22

Metadata

Authors
Jones, R. N.
Venue
Clinical Microbiology and Infection
Publisher
Elsevier BV
Published
2008-03
Volume
14
Pages
3-9
ISSN
1198-743X
Cited by
22
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Key considerations in the treatment of complicated staphylococcal infections. https://app.cochat.ai/papers/10.1111/j.1469-0691.2008.01923.x
The paper
Jones, R. N. (2008). Key considerations in the treatment of complicated staphylococcal infections. Clinical Microbiology and Infection. https://doi.org/10.1111/j.1469-0691.2008.01923.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.